Streetbeat News

Products Services

NUZE

NuZee has entered into a five-year global licensing agreement with Stone Brewing. Under the agreement, NuZee will co-manufacture and distribute Stone Brewing specialty coffee products nationwide. The new product line is expected to launch in Q3 2023.

Portfolio Pulse from Benzinga Newsdesk

July 07, 2023 | 11:33 am

CTSO

Cytosorbents has completed enrollment in the pivotal Safe and Timely Antithrombotic Removal – Ticagrelor trial. The trial is evaluating the ability of DrugSorb-ATR to reduce perioperative bleeding in patients undergoing cardiothoracic surgery on Ticagrelor.

Portfolio Pulse from Benzinga Newsdesk

July 07, 2023 | 11:23 am

BIIB

Biogen's shares resumed trading and rose 2.5% following the FDA's approval of its Alzheimer's drug, Leqembi, on Thursday.

Portfolio Pulse from Charles Gross

July 07, 2023 | 11:16 am

BRTX

BioRestorative Therapies' drug candidate BRTX-100 has passed safety tests and is moving ahead with Phase 2 of its development. This is a significant milestone for the company and could potentially impact its stock price.

Portfolio Pulse from Benzinga Newsdesk

July 07, 2023 | 11:08 am

BCLI

BrainStorm Cell Therapeutics has announced that data shows treatment with NurOwn significantly reduces NfL, a key biomarker of neurodegeneration. The treatment also elevated markers of neuroprotection and lowered markers of neuroinflammation.

Portfolio Pulse from Benzinga Newsdesk

July 07, 2023 | 11:06 am

LLY

NVO

Novo Nordisk's weight-loss drug Wegovy has been successful but has side effects like severe nausea, leading to discontinuation by many users. This has sparked interest from investors and biotech companies to develop alternative weight-loss drugs with fewer side effects. Companies like Rivus Pharmaceuticals, Glyscend Therapeutics, and Antag Therapeutics are developing such alternatives. Major pharmaceutical companies like Novo Nordisk and Eli Lilly are also working on second-generation weight-loss drugs.

Portfolio Pulse from Vandana Singh

July 07, 2023 | 11:06 am

AXSM

Axsome Therapeutics has dosed the first patient in the FOCUS Phase 3 trial of Solriamfetol, an investigational treatment for Attention Deficit Hyperactivity Disorder in adults.

Portfolio Pulse from Benzinga Newsdesk

July 07, 2023 | 11:04 am

CSTL

Castle Biosciences will present new data on its DecisionDx-SCC and DecisionDx-melanoma tests at the American Head & Neck Society's International Conference on Head and Neck Cancer. This could potentially increase the visibility and credibility of the company's products.

Portfolio Pulse from Benzinga Newsdesk

July 07, 2023 | 11:03 am

FSR

Fisker Inc. (NYSE:FSR) announced its Q2 2023 vehicle production volume, with 1,022 Fisker Ocean SUVs produced in Austria for customers and other purposes. The company faced challenges from suppliers not receiving components on time, but still exceeded its targeted assembly rate of 80 units per day by the end of June. Fisker is investing in additional battery pack capacity to support higher volumes next year. The company will report its Q2 2023 financial results on August 4, 2023.

Portfolio Pulse from Charles Gross

July 07, 2023 | 10:59 am

BTAI

LEVI

LXRX

RIOT

SENS

VRNS

Several US stocks are trading lower in the pre-market session. Levi Strauss & Co. (LEVI) shares dipped 8.2% despite reporting upbeat Q2 earnings, as the company lowered its annual profit outlook. BioXcel Therapeutics (BTAI) shares fell 7.4% following the release of topline results for a Phase 3 trial of BXCL501 for Alzheimer's disease-related agitation. Senseonics Holdings (SENS) shares dropped 5.4% after reporting equity grants to employees. Varonis Systems (VRNS) shares declined 4.8%, Lexicon Pharmaceuticals (LXRX) shares fell 3.2%, and Riot Platforms (RIOT) shares slipped 2.5% after issuing production and operations updates.

Portfolio Pulse from Lisa Levin

July 07, 2023 | 10:48 am